{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-043042","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2026-06-15T13:18:44+00:00","discovered_at":"2026-06-15T13:20:00.485693+00:00","generated_at":"2026-06-15T13:20:10.600838+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Context Therapeutics reports 29% ORR for CTIM-76 in Phase 1 PROC trial; FDA Fast Track granted","bullets":["29% confirmed overall response rate per RECIST v1.1 in heavily pretreated PROC patients (median 7 prior lines).","Cytokine Release Syndrome limited to Grade 1 in 11% of PROC patients at active doses; supports outpatient dosing.","PK data supports exploration of Q3W dosing in 2H 2026; Phase 1b dose expansion planned for 2027.","CTIM-76 granted FDA Fast Track Designation for platinum-resistant ovarian cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-043042","json":"https://secwatch.observer/filing/0001628280-26-043042.json","markdown":"https://secwatch.observer/filing/0001628280-26-043042.md","text":"https://secwatch.observer/filing/0001628280-26-043042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026043042/0001628280-26-043042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026043042/cntx-20260615.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:20:10.600838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}